Allianz Asset Management GmbH Reduces Position in Hologic, Inc. $HOLX

Allianz Asset Management GmbH trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 48.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 62,819 shares of the medical equipment provider’s stock after selling 59,775 shares during the quarter. Allianz Asset Management GmbH’s holdings in Hologic were worth $4,240,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its stake in Hologic by 294.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after purchasing an additional 8,227,318 shares in the last quarter. Invesco Ltd. grew its position in shares of Hologic by 72.5% in the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after purchasing an additional 3,505,828 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Hologic by 1.7% in the second quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock valued at $378,209,000 after purchasing an additional 97,142 shares during the last quarter. Black Creek Investment Management Inc. lifted its position in Hologic by 26.1% during the second quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock worth $262,453,000 after buying an additional 832,444 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in Hologic by 2.2% during the second quarter. Bank of America Corp DE now owns 3,090,306 shares of the medical equipment provider’s stock worth $201,364,000 after buying an additional 66,453 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of recent research reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $78.00 target price on shares of Hologic in a research note on Wednesday, October 22nd. Morgan Stanley raised their price objective on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Stephens lowered shares of Hologic from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $78.00 to $76.00 in a report on Wednesday, October 22nd. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Raymond James Financial cut Hologic from a “moderate buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Two research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, Hologic presently has a consensus rating of “Hold” and an average price target of $78.42.

Hologic Trading Up 0.2%

Shares of NASDAQ HOLX opened at $75.15 on Wednesday. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $16.78 billion, a PE ratio of 31.31, a PEG ratio of 2.24 and a beta of 0.72. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $75.36. The stock has a fifty day simple moving average of $74.88 and a 200-day simple moving average of $71.44.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business’s revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.87 earnings per share. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.